Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Other solid neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 50Carcinoma, Non-Small-Cell Lung 50Carcinoma, Renal Cell 37Carcinoma, Hepatocellular 20Neoplasm Metastasis 19Lung Neoplasms 19Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Stomach Neoplasms 15Colorectal Neoplasms 15Carcinoma, Transitional Cell 14Adenocarcinoma Of Esophagus 12Prostatic Neoplasms 10Hodgkin Disease 10Brain Neoplasms 10Urinary Bladder Neoplasms 8Ovarian Neoplasms 8Multiple Myeloma 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Pancreatic Neoplasms 7Esophageal Neoplasms 7Breast Neoplasms 7Colonic Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Basal Cell 6Uveal Melanoma 5Uterine Cervical Neoplasms 5Thyroid Neoplasms 5Sarcoma 5

Interventions

durvalumab 8Bevacizumab 7tremelimumab 4lenvatinib 3atezolizumab 3Nivolumab 3Ipilimumab 3fludarabine 2Magnetic Resonance Imaging 2Hepatectomy 2Gemcitabine 2Cyclophosphamide 2Cisplatin 2trastuzumab deruxtecan 1toripalimab 1ropidoxuridine 1poly ICLC 1pembrolizumab 1brodalumab 1Whole Genome Sequencing 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radionuclide Imaging 1Pluvicto 1Platinum 1Paclitaxel 1Laparoscopy 1Immunotherapy, Adoptive 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Liver Neoplasms × Nivolumab × 90 days × Clear all
NCT03143270 2026-05-07

A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Active not recruiting
20 enrolled
Gastrointestinal

Liver Neoplasms

NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Not yet recruiting
27 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡